LENZ Therapeutics, Inc. (LENZ) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
445 Marine View Avenue
Solana Beach, CA 92014
United States of America (the)
Phone
(858) 925-7000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
152
First IPO Date
March 22, 2024
| Name | Title | Pay | Year Born |
| Evert Schimmelpennink | President, Chief Executive Officer, Secretary & Director | 1.24M | 1972 |
| James W. McCollum | Co-Founder & Director | 40,000 | 1955 |
| Daniel R. Chevallard | Chief Financial Officer | 680,368 | 1980 |
| Shawn Olsson | Chief Commercial Officer | 724,600 | 1983 |
| Marc G. Odrich | Chief Medical Officer | 774,000 | 1959 |
| Kris Gambelin | Senior Vice President of Regulatory & Clincal Operations | 0 | N/A |
| David Choromanski | Vice President of Marketing | 0 | N/A |
| Domenick Porfidia | Vice President of Sales | 0 | N/A |
| Melissa Rosness | Senior Vice President of Manufacturing Operations | 0 | N/A |
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.